Everolimus is an orally administered mTOR inhibitor. The effect, and mechanism of action, of everolimus on lung cancers with an epidermal growth factor receptor (EGFR) mutation remain unclear. Four gefitinib-sensitive and -resistant cell lines were used in the present work. Growth inhibition was determined using the MTT assay. Transgenic mice carrying the EGFR L858R mutation were treated with everolimus (10 mg/kg/day), or vehicle alone, from 5 to 20 weeks of age, and were then sacrificed. To evaluate the efficacy of everolimus in prolonging survival, everolimus (10 mg/kg/day) or vehicle was administered from 5 weeks of age. The four cell lines were similarly sensitive to everolimus. Expression of phosphorylated (p) mTOR and pS6 were suppressed upon treatment with everolimus in vitro, whereas the pAKT level increased. The numbers of lung tumors with a long axis exceeding 1 mm in the everolimus-treated and control groups were 1.9 ± 0.9 and 9.4 ± 3.2 (t-test, p<0.001), respectively. pS6 was suppressed during everolimus treatment. Although apoptosis and autophagy were not induced in everolimus-treated EGFR transgenic mice, angiogenesis was suppressed. The median survival time in the everolimus-treated group (58.0 weeks) was significantly longer than that in the control group (31.2 weeks) (logrank test, p<0.001). These findings suggest that everolimus had an indirect effect on tumor formation by inhibiting angiogenesis Abbreviations: EGFR, epidermal growth factor receptor; eIF4E, eukaryotic translation initiation factor complex 4E; 4E-BP, 4E-binding protein; mTOR, mammalian target of rapamycin; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; NSCLC, non-small cell lung cancer; pS6, phospho-S6 ribosomal protein; TKI, tyrosine kinase inhibitor.
Introduction
Somatic mutants of the epidermal growth factor receptor (EGFR), HER2, KRAS, BRAF, PIK3CA, and EML4-ALK of non-small cell lung cancers (NSCLCs) are viewed as targets of anti-cancer agents [1] . Of tumors in 52 East Asian never-smokers with lung adenocarcinomas, 78.8% harbored EGFR mutations, 5.8% (three) EML4-ALK fusions, 3.8% (two) HER2 mutations, and 1.9% (one) a KRAS mutation.
Only 9.6% (five of 52) tumors did not harbor any of these known oncogenic driver mutations [2] . Never-smokers with NSCLC could be divided into four distinct genotypic groups based on genetic profiling of three major oncogenes (EGFR, EML4-ALK, and KRAS), yielding unique and non-overlapping subsets of patients with lung cancer who exhibited different therapeutic responses and survival outcomes [3] .
The "Biomarker-integrated approaches of targeted therapy for lung cancer elimination" (BATTLE) program of personalized medicine has been recently developed [4] . Adaptive randomization was successfully used to assign NSCLC patients to the treatment offering the greatest potential benefit, based on the markers of prospectively biopsied tumors.
Moreover, EGFR mutations and EML4-ALK gene rearrangements in NSCLC have been established as real molecular targets from the clinical studies [5] . Thus, it is important to treat patients with reference to their genetic profiles to determine whether patients can 6 benefit from specifically targeted therapies.
EGFR mutations are more frequently observed in females, non-smokers, and adenocarcinoma patients, especially in Asian populations, wherein the mutation rate is 30-50% [6] . The EGFR tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib, improved progression-free survival in patients with NSCLC harboring EGFR mutations [7] [8] [9] [10] [11] . The majority of EGFR mutant lung cancers initially sensitive to EGFR-TKI become resistant to these agents within 1 year. Some possible mechanisms for acquisition of resistance have been identified, the most common being development of an EGFR T790M "gatekeeper" mutation in about 50% of cases [12] [13] . Although clinical work seeking to overcome resistance acquired via T790M has been conducted, no generally accepted therapy has been established [14] .
The mammalian target of rapamycin (mTOR) is located downstream of EGFR and plays a major role in regulation of protein translation, cell growth, and metabolism [15] [16] [17] [18] . Alterations in the mTOR signaling pathway are common in cancer patients and mTOR is being actively explored as a therapeutic target [17] . Inhibition of mTOR by targeting agents causes G1 cell-cycle arrest mediated by inactivation of phospho-S6 ribosomal protein (pS6) and hypophosphorylation of 4E-BP1 [16] . Everolimus is an orally administered rapamycin analog showing anticancer effects on renal cell 7 carcinoma and pancreatic neuroendocrine tumors [17] . Furthermore, in preclinical studies, everolimus showed anticancer effects in various cancer cell lines and xenograft models, including lung cancer [16] . However, the effect of mTOR inhibitors on NSCLC harboring EGFR mutations remains unclear. In our present study, we investigated the preclinical efficacy of everolimus in NSCLC harboring EGFR mutations. Our findings suggest that everolimus might be effective for NSCLC by the inhibiting tumor angiogenesis.
Materials and Methods

Cell lines and mouse model
PC-9 is a lung adenocarcinoma cell line that has an in-frame deletion mutation at exon 19 of EGFR and amplification of the EGFR gene. We used RPC-9 cells with the T790M mutation of EGFR that were 400-fold more resistant to gefitinib than parental PC-9 cells [19] . The RPC-9 cell line was established in our laboratory by continuously exposing the PC-9 cell line to gefitinib. H3255 is a lung adenocarcinoma cell line that has a L858R point mutation at exon 21 of EGFR and amplification of the EGFR gene. We generated transgenic mice expressing the L858R mutation of EGFR driven by the SP-C promoter [20] . In the absence of treatment, these transgenic mice developed atypical adenomatous hyperplasia at 4 weeks of age and adenocarcinoma at 6 to 7 weeks of age, and died from tumor progression at 25 to 40 weeks. The transgenic mice were randomly assigned to two groups that received either vehicle alone or everolimus (10 mg/kg/day) from 5 to 20 weeks of age. Vehicle and everolimus were administered once a day, five times a week, by gavage. Body weights were determined 
Sensitivity test
Everolimus was the kind gift of Novartis. Drug sensitivity was evaluated using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay [21] . The 9 cells were added to wells of 96-well plates at a density of 2,000 cells per well and exposed continuously to the drug for 96 h. The reason for which MTT assay was done with 96 h of drug incubation was that our previous study showed the cell viability assay with 96 h drug exposure could replace standard human clonogenic assay in evaluating the effects of anticancer agents [22] . The 50% inhibitory concentration (IC 50 ) of everolimus was determined by plotting the logarithm of drug concentration versus the proportion of survivors. Each assay was performed in triplicate or quadruplicate.
Immunoblotting
Protein extracts were prepared from crushed tissue samples that had been suspended in mM NaCl, 1 mM EDTA, 1 mM EGTA, 10 mM β-glycerol phosphate, 10 mM NaF, and 1 mM Na-orthovanadate) containing protease inhibitors (Roche Diagnostics, Basel, Switzerland) and centrifuged at 15,000 rpm for 20 min at 4°C. After quantification using a Bio-Rad (Bio-Rad, Hercules, CA) protein assay, ~50 μg of protein were subjected to 5-15% SDS-PAGE (Bio-Rad) and then transferred to nitrocellulose membranes. Specific proteins were detected by the enhanced chemiluminescence assay (GE Healthcare, Buckinghamshire, UK) using antibodies (from Cell Signaling unless otherwise indicated) against EGFR (1:1,000 dilution), mTOR (1:1,000 dilution), AKT
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(1:1,000 dilution), MAPK (1:1,000 dilution), PI3K (1:5,000 dilution; Upstate), S6, 4E-binding protein (4E-BP) (1:1,000 dilution), pEGFR (1:1,000 dilution), pmTOR (1:1,000 dilution), pAKT (1:1,000 dilution), pMAPK (1:1,000 dilution), pS6 (1:1,000 dilution), p4E-BP (1:1,000 dilution),-actin (1:1,000 dilution), Beclin1 (1:1,000 dilution), ATG5 (1:1,000 dilution), ATG7 (1:1,000 dilution), LC3B (1:1,000 dilution), PARP (1:1,000 dilution), and cleaved PARP (1:1,000 dilution). The secondary antibodies used were anti-rabbit and anti-mouse IgG (horseradish peroxidase-linked, species-specific whole antibodies; GE Healthcare), both of which were used at a 1:5,000 dilution.
Immunohistochemistry
Formalin-fixed paraffin-embedded tissue blocks of samples were cut to a thickness of 5 m, placed on glass slides, and deparaffinized in xylene and a graded series of alcohol baths for 10 minutes. The sections were incubated in 10 mmol/L sodium citrate buffer, 
Statistical analysis
Statistical analysis was performed using the SPSS Base System TM and Advanced Statistics TM programs (SPSS, Chicago, IL). Group differences were compared using Student's t-test. Survival time was defined as the period from initiation of treatment to death. Overall survival curves were calculated using the Kaplan-Meier method.
P-values ≤ 0.05 were considered to be statistically significant.
Results
Everolimus was effective regardless EGFR mutation status.
Sensitivity to everolimus of lung cancer cell lines was examined at first.
Everolimus exhibited similar efficacy on A549 cells (EGFR wild-type), H3255 cells (with the L858R mutation), PC-9 cells (with an exon 19 deletion mutation) and RPC-9 cells (with both the exon 19 deletion mutation and the T790M mutation). The curves of 12 concentration versus surviving fraction were similar and all IC 50 s were around 0.01 M ( Figure 1A , 1B).
Everolimus suppressed pmTOR and pS6.
Next, effect of everolimus on EGFR-related signals was examined using immunoblotting. pmTOR and pS6 in H3255 cells were suppressed by treatment with everolimus, whereas pAKT increased in level, presumably due to negative feedback from mTOR inhibition ( Figure 1C ). Similar results were obtained in PC-9 and RPC-9 cells (Supplemental figure 1) . However, in Figure 1C , both pS6 and mTOR levels were increased with increasing concentrations of everolimus. Thus, high dose of everolimus might increase pS6 and pmTOR as a result of negative feedback from AKT or mTORC2
[23, 24]. Furthermore, everolimus had no effect on p4E-BP ( Figure 1C , Supplemental figure 1). Although rapamycin decreased p4E-BP levels in NSCLC lines [25] , everolimus had a variety of effects (increase, decrease or no change) on p4E-BP, dependent on treatment dose and duration [18] . A matter of degree of AKT activation by inhibiting mTOR might cause such results [24, 25].
The lung tumors in EGFR transgenic mice responded to everolimus.
Firstly, proteins downstream of EGFR were evaluated in transgenic mice. Figure 2A showed that pmTOR, pS6 and p4E-BP were overexpressed. Thus, the mTOR 13 might be a therapeutic target in EGFR transgenic mouse models although mTOR is not the only protein downstream EGFR to be activated ( Figure 1C, 2A) .
Secondary, antitumor effect of everolimus on EGFR transgenic mice which received either everolimus (10 mg/kg/day) or vehicle from 5 to 20 weeks of age (15 weeks-treatment) was evaluated. The mean numbers (± SD) of superficial lung tumors (of long axis exceeding 1 mm) in the everolimus-treated and control group were 1.9 ± 0.9 (n = 14) and 9.4 ± 3.2 (n = 13) (Student's t-test, p<0.001), respectively ( Figure 2B ).
Hematoxylin-eosin (H.E.) staining revealed that everolimus prevented progression of lung tumors ( Figure 3A ). pS6 was suppressed during everolimus treatment, although the pmTOR and p4E-BP levels were similar ( Figure 3B ). When the mice having more advanced lung tumors at age of 15 weeks were treated with everolimus (10 mg/kg/day) or vehicle for one week, pS6 and pmTOR expressions were decreased and p4E-BP expression was similar in the everolimus-treated mice compared with the vehicle-treated mice (Supplemental figure 2) . In this situation, the tumors did not respond to one week-treatment with everolimus (data not shown). These results suggest that treatment duration and timing of administration of everolimus may affect the proteins downstream of EGFR.
Thirdly, we treated the transgenic mice with everolimus (10 mg/kg/day) or 14 vehicle for 5 weeks. They had early (at age of 5 weeks) or advanced (at age of 12 weeks) lung tumors and received either drug from 5 to 10 weeks of age (n =4 for vehicle and n = 7 for everolimus) or from 12 to 17 weeks (n = 3 for vehicle and n = 4 for everolimus), respectively. The lung tumors in the sacrificed mice at 10 weeks of age and at 17 weeks of age responded to everolimus (Supplemental figures 3 and 4, respectively).
Everolimus prolonged survival in EGFR transgenic mice.
Subsequently, efficacy of everolimus on survival of EGFR transgenic mice was evaluated. The median survival time of the everolimus-treated group (58.0 weeks) was significantly longer than that of the vehicle group (31.2 weeks) (logrank test, p<0.001) ( Figure 4A ). The body weights of the everolimus-treated and vehicle groups did not significantly differ ( Figure 4B ). No apparent adverse event was noted in everolimus-treated mice. 
Everolimus inhibited angiogenesis.
Discussion
We found that everolimus was similarly efficacious, in vitro, on cells harboring various EGFR mutations. The EGFR-tyrosine kinase inhibitor resistance-related T790M secondary mutation seemed to be neutralized by everolimus ( Figure 1B ). In addition, everolimus suppressed lung tumors in transgenic mice expressing the L858R mutation of EGFR and prolonged the overall survival of these mice.
Signaling pathways of AKT/mTOR that include S6, 4E-BP, or the eukaryotic translation initiation factor complex 4E (eIF4E), have been reported to be associated with prognosis of NSCLC. Anagnostou et al. found that a high mTOR protein level were an independent favorable prognostic factor for surgically resected adenocarcinoma of the lung [31] . Yoshizawa et al. found that expression of peIF4E, in addition to pAKT, predicted poor prognosis of surgically resected NSCLC but pmTOR expression was not a prognostic factor [32] . Dhillion et al. reported that high-level mTOR expression significantly predicted poor survival in resected stage IA-IIB NSCLC patients [33] . Liu et al. found that the levels of mTOR, pmTOR, pAKT, and pS6 in surgically resected primary NSCLC were higher than in the wild-type lung [34] . In this study, overall survival was significantly shorter in cases positive for pmTOR, pPDK1, and pS6. Thus, although AKT/mTOR-related proteins are often overexpressed in NSCLC, the prognostic implications remain unclear. In our EGFR transgenic mice, mTOR and 4E-BP were activated (Figure 2A ). Everolimus suppressed pmTOR and pS6 but not p4E-BP, and increased pAKT (via negative feedback) in vitro ( Figure 1C) . Also, everolimus suppressed pS6 but not pmTOR and p4E-BP in vivo ( Figure 3B ).
Conceivably, everolimus may act on different signaling pathways in vitro and in vivo.
Our results using transgenic mice suggest that marked suppression of pS6 by everolimus might be important in this respect.
Apoptosis and autophagy were enhanced in response to exposure to mTOR inhibitors [26] [27] [28] [29] [30] . Tumor inhibition mediated by mTOR inhibitors seemed to involve antiangiogenic activity, correlating with impaired vascular endothelial growth factor (VEGF) production and blockage of VEGF-induced vascular endothelial cell stimulation by enhancement of hypoxia inducible factor-1 (HIF-1) degradation [17, 35] .
Although apoptosis and autophagy were not induced in everolimus-treated EGFR transgenic mice ( Figure 5B ), angiogenesis was suppressed ( Figure 6 ). Indeed, even EGFR-TKIs induced both apoptosis and autophagy in EGFR-mutated NSCLC cells in vitro [36, 37] . However, whether autophagy causes cancer cell death or confers a survival advantage on tumor cells under stressful conditions remains unclear [37, 38] .
Everolimus may control autophagy in cancer cells although we do not know why the in vitro and in vivo data differ. Recently, two mTOR inhibitors (temsirolimus and everolimus) were shown to suppress the growth of EGFR mutant lung cancer cells in vitro and in vivo [39] . Also, temsirolimus markedly inhibited cell angiogenesis in both PC-9-and EGFR-TKI-resistant (PC-9/HGF) xenograft tumors. We found that everolimus exhibited similar efficacy when added to cultures of four EGFR-TKIsensitive and -insensitive cells in vitro, and everolimus suppressed tumor growth and prolonged survival in EGFR-mutated transgenic mice. Thus, our present data support their findings. Although some reports have shown that combination of an mTOR inhibitor with EGFR-TKI was an effective therapy [40] [41] [42] , the possible value of everolimus monotherapy of EGFR-mutated lung cancer cells has been shown only by Ishikawa et al. [39] and us. A strength of our study is that we first showed that lung tumors in EGFR-transgenic mice were sensitive to everolimus, and the drug prolonged survival. However, it is very unlikely that EGFR mutant lung cancer will ever be treated without the presence of an EGFR-TKI [14] . Naturally, gefitinib was effective for the EGFR transgenic mice [20] . The median survival in the mice (n = 13) treated with gefitinib was more than 100 weeks (Supplemental figure 6 ). EGFR mutant lung cancer patients who were refractory to EGFR-TKIs might have benefits from the treatment 19 with everolimus. Thus, a weakness of our study is that we could not discover whether EGFR-TKI-resistant transgenic mice with a T790M secondary mutation were also sensitive to everolimus alone because we did not have such mice.
In a phase II study [43] , advanced NSCLC patients, who had undergone two or fewer prior chemotherapy regimens, one platinum-based (stratum 1); or both chemotherapy and EGFR-TKI treatment (stratum 2); received everolimus (10 mg/day).
Eighty-five patients were enrolled, 42 in stratum 1 and 43 in stratum 2. The overall response rate was 4.7% (7.1% in stratum 1; 2.3% in stratum 2) and the overall disease control rate 47.1%. Only 11 cases were evaluated for EGFR mutations and none was detected. Although everolimus showed modest clinical activity when given to heavily pretreated patients with advanced-stage NSCLC, the clinical activity of everolimus in NSCLC patients harboring EGFR mutations should be further evaluated. In conclusion, our present study suggested that everolimus might be effective to treat EGFR-mutated lung cancer and had an indirect effect on tumor formation by inhibiting angiogenesis.
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Figure legends h. pmTOR and pS6 were suppressed by treatment with everolimus, whereas the pAKT level was increased, presumably due to negative feedback from mTOR inhibition. A) The median survival time in the everolimus-treated group was significantly longer than that in the vehicle group (log-rank test, p<0.001).
B) There was no significant difference in the body weights of the everolimus-treated and vehicle-treated group. Bars indicate SE. 6. The survival curve of the EGFR transgenic mice treated with gefitinib.
The median survival in the mice (n = 13) treated with gefitinib was more than 100 weeks. Supplemental Figure 6 
